Global Hemoglobinopathies Drugs Market By Product Type (Thalassemia Therapy, Sickle Cell Disease(SCD) Therapy) And By End-Users/Application (Alpha Thalassemia, Beta thalassemia) Global Market Share, Forecast Data, In-Depth Analysis, And Detailed Overview, and Forecast, 2013 - 2026

  • AMR-984924
  • April 2021
  • Pharmaceuticals
  • 118 Pages

Report Preview

The Hemoglobinopathies Drugs Market research report comprises of an overall in depth-analysis such as market drivers, opportunities, restraints, latest developments and trends, segmentation of the market, competitive analysis, global as well as regional analysis by showcasing how each of these factors can improve the further growth of the market on an overall perspective. The report also showcases the overall market value which includes the historic data (2018-2019) and forecast data (2020-2028) generated through the revenue (USD Mn)

The Hemoglobinopathies Drugs Market has been valued at US$ xx Mn in the year 2020 and is anticipated to attain US$ xx Mn by the year 2028 along with a CAGR of xx%

Hemoglobinopathies Drugs Report’s Assessment
The research report is formulated such that it offers a deep understating on the market drivers that are assimilating the growth of the market, the market opportunities that are going to provide future growth factors for the market and the market restraints which showcase the reasons as to why the market can get hampered and dissimilated. All these factors are considered keeping in view the historic and forecast analysis which can enlighten the above mentioned factors.

Thereby at a glance a reader can understand all the factors and prospects of the Hemoglobinopathies Drugs market and how it can assimilate and dissimilate based on each of the factors and figures mentioned in the report
 
Report Parameters Details of Parameter
Market Size xx Million
Based Year 2019
Forecast Period Covered 2019 – 2028
Units for value Revenue in USD million and CAGR from 2020 to 2028
Covered Segments Component, Types, Applications, End-Users, and more.
Product Type Thalassemia Therapy, Sickle Cell Disease(SCD) Therapy, Other Therapy
Applications Alpha Thalassemia, Beta thalassemia, Sickle Cell Disease, Hb Variants Diseases
Region Covered North America, Europe, Asia Pacific, Latin America, Middle East and Africa
Companies Covered Gamida Cell, Alnylam Pharmaceuticals, Biogen Idec, Sangamo BioSciences Inc., Genetix Pharmaceuticals/Bluebird Bio, Global Blood Therapeutics Inc., Pfizer Inc., Mast Therapeutics, Emmaus Life Sciences, Inc., Prolong Pharmaceuticals, Celgene Corporation, HemaQuest Pharmaceuticals
 
Hemoglobinopathies Drugs Market Competitive and Premeditated Analysis
In the Hemoglobinopathies Drugs report major factors such latest tactical developments, competitors, research and development, participation of each region in the market and the competition among them, the latest news regarding company acquisitions and product launch, revenue of the competitors as well as the key offerings they provide all these factors are mentioned in the report with reasons to justify and understand them in depth.

The readers and purchaser of the Hemoglobinopathies Drugs research report can gain a comprehensive understanding of the market competition, the revenue of each major players and their contribution towards the market, attractive proposition analysis is provided in the report which sub divides the segments with respect to the largest segment that has contributed to the market growth and the fastest growing segment based on the size of the market as well as its overall appeal.
 
Hemoglobinopathies Drugs Market Segmentation Analysis:
The Hemoglobinopathies Drugs market is segmented into various sections such as product types, applications as well as end users and regions. Each of the segment is explained in brief along with the revenue it generates for the market based on the historic and forecast data by highlighting the largest segment and the fastest growing segment with reasons to justify it.

Segmentation based on type includes Thalassemia Therapy, Sickle Cell Disease(SCD) Therapy, Other Therapy   

The application segment includes   Alpha Thalassemia, Beta thalassemia, Sickle Cell Disease, Hb Variants Diseases

Major Key Players for Global Hemoglobinopathies Drugs Market:
The Hemoglobinopathies Drugs market research report offers the company profile of major key players including progress trends, competitive landscape breakdown, and key in regions development status. Gamida Cell, Alnylam Pharmaceuticals, Biogen Idec, Sangamo BioSciences Inc., Genetix Pharmaceuticals/Bluebird Bio, Global Blood Therapeutics Inc., Pfizer Inc., Mast Therapeutics, Emmaus Life Sciences, Inc., Prolong Pharmaceuticals, Celgene Corporation, HemaQuest Pharmaceuticals
 
The Hemoglobinopathies Drugs market report showcases vast potentials of growth and assimilation which is going to provide the industry numerous opportunities to grow and generate revenue by understanding the segments and which segment is a potential part to increase the disposable income in the present and upcoming years.

Regional Analysis of the Hemoglobinopathies Drugs market:
The Hemoglobinopathies Drugs market is dived based on different regions such as North America, Europe, Asia Pacific, Latin America and the Middle East and Africa. And the analysis of each region is provided by highlighting the largest contribution region, the fastest growing region and the factors that is keeping the market active in the other regions is also mentioned in depth. Each regional segment also comprises of the revenue each segment holds in a specific region with reasons to justify the values.

The Global segmentation of the Hemoglobinopathies Drugs market:
By Type:
  • Thalassemia Therapy
  • Sickle Cell Disease(SCD) Therapy
  • Other Therapy

By Application
  • Alpha Thalassemia
  • Beta thalassemia
  • Sickle Cell Disease
  • Hb Variants Diseases

By Regions:
  • North America (U.S and Canada)
  • Europe (U.K., Germany and France)
  • Asia Pacific (China, India and Japan)
  • Latin America (Mexico and Brazil)
  • Middle East and Africa (GCC Countries and South Africa)
 


 
Major Factors Included and highlighted in the Hemoglobinopathies Drugs report are as follows:
  • The overall market value along with historic and future data analysis.
  • The Growth drivers, opportunities and restraints are mention in detail.
  • The size of the entire Hemoglobinopathies Drugs market on a global perspective.
  • The CAGR value of the overall market from 2020 to 2028.
  • COVID-19 impact on the Hemoglobinopathies Drugs market and how it is coping up with the situation.
  • Major competitors and their contribution towards the market.
  • The segmentation analysis is included which provides a clear picture of the market bifurcation.
  • Tables and graphs that can easily been understood at a glance
  • Latest trends and news related to the Hemoglobinopathies Drugs market is included in the report.
 
Key Analytical Areas:
The report aims to offer a complete solution to various businesses operating in the Hemoglobinopathies Drugs market in making strategic decisions based on credible information and actionable insights. Thereby, the report covers various aspects of your requirements such as industry overview, market dynamics, regional analysis and competitive landscape. The report aims to provide insights to businesses in the Hemoglobinopathies Drugs market for numerous purposes such as:

     1. Strategic Decision Making:
With the help of this report, key decision makers can quickly analyze and identify growth opportunities in terms of numerous segments across various geographical regions. Thereby, this report enables organizations to identify and make strategic investments in specific market segments in order to gain maximum return on investment.

     2. Actionable Insights:
The report offers a deep dive into how companies are leveraging market conditions to make the most in the Hemoglobinopathies Drugs market. Thereby, the report offers numerous actionable insights into the best practices and key success factors relevant in the Hemoglobinopathies Drugs market. Using the insights included in the report, businesses can make quick decisions to achieve success in business operations.

     3. Competitive Snapshot:
In addition, to detailed information on the companies operating in the Hemoglobinopathies Drugs market, the report also includes a competitive snapshot of all the companies covered in the report. Thereby, this offers a visual representation of how all the companies stand comparatively based on their competencies, geographic presence, market hold, years of operations, employee and financial strength, among others.

Manufacturers and Segments

Have query on this report?

Make an Enquiry
1. Preface
     1.1. Report Scope and Description
     1.2. Research Methodology
          1.2.1. Phase I-Secondary Research
          1.2.2. Phase II-Primary Research
          1.2.3. Phase II-Expert Panel Review
          1.2.4. Assumptions
          1.2.5. Approach Adopted

2. Executive Summary
     2.1. Global Hemoglobinopathies Drugs Market Snapshot
          2.1.1. Global Hemoglobinopathies Drugs Market By Type,2019
               2.1.1.1.Thalassemia Therapy
               2.1.1.2.Sickle Cell Disease(SCD) Therapy
               2.1.1.3.Other Therapy
          2.1.2. Global Hemoglobinopathies Drugs Market By Application,2019
               2.1.2.1.Alpha Thalassemia
               2.1.2.2.Beta thalassemia
               2.1.2.3.Sickle Cell Disease
               2.1.2.4.Hb Variants Diseases
          2.1.3. Global Hemoglobinopathies Drugs Market By End-use,2019
          2.1.4. Global Hemoglobinopathies Drugs Market By Geography,2019

3. Global Hemoglobinopathies Drugs Market Dynamics
     3.1. Market Overview
     3.2. Market Inclination Insights Analysis
     3.3. Drivers
     3.4. Challenges
     3.5. Future Prospects
     3.6. Impact Analysis of Drivers and Challenges During the Forecast Period, (2020-2028)

4. Global Hemoglobinopathies Drugs Market Size (US$), By Type, 2018 – 2028 
     4.1. Overview
          4.1.1. Market Share Analysis By Type, 2019 vs.2028
          4.1.2. Attractive Investment Proposition By Type, 2020
     4.2. Global Hemoglobinopathies Drugs Market Size (US$), By Type, 2018 – 2028

5. Global Hemoglobinopathies Drugs Market Size (US$), By Application, 2018 – 2028 
     5.1. Overview
          5.1.1. Market Share Analysis By Application, 2019 vs.2028
          5.1.2. Attractive Investment Proposition By Application, 2020
     5.2. Global Hemoglobinopathies Drugs Market Size (US$), By Application, 2018 – 2028

6. Global Hemoglobinopathies Drugs Market Size (US$), By End-use, 2018 – 2028 
     6.1. Overview
          6.1.1. Market Share Analysis By End-use, 2019 vs.2028
          6.1.2. Attractive Investment Proposition By End-use, 2020
     6.2. Global Hemoglobinopathies Drugs Market Size (US$), By End-use, 2018 – 2028

7. Global Hemoglobinopathies Drugs Market Size (US$), By Geography, 2018 – 2028
     7.1. Overview
          7.1.1. Market Share Analysis by Geography, 2019 vs. 2028
          7.1.2. Attractive Investment Proposition by Geography, 2020
     7.2. North America Hemoglobinopathies Drugs Market Analysis, 2018 – 2028 
          7.2.1. North America Hemoglobinopathies Drugs Market Size (US$), By Country, 2018 – 2028 
               7.2.1.1. U.S.
               7.2.1.2. Canada
          7.2.2. North America Hemoglobinopathies Drugs Market Size (US$), By Type, 2018 – 2028
          7.2.3. North America Hemoglobinopathies Drugs Market Size (US$), By Application, 2018 – 2028
          7.2.4. North America Hemoglobinopathies Drugs Market Size (US$), By End-use, 2018 – 2028
     7.3. Europe Hemoglobinopathies Drugs Market Analysis, 2018 – 2028 
          7.3.1.  Europe Hemoglobinopathies Drugs Market Size (US$), By Country, 2018 – 2028 
               7.3.1.1. U.K.
               7.3.1.2. Germany
               7.3.1.3. France
               7.3.1.4. Rest of Europe
          7.3.2. Europe Hemoglobinopathies Drugs Market Size (US$), By Type, 2018 – 2028
          7.3.3. Europe Hemoglobinopathies Drugs Market Size (US$), By Application, 2018 – 2028
          7.3.4. Europe Hemoglobinopathies Drugs Market Size (US$), By End-use, 2018 – 2028
     7.4. Asia Pacific Hemoglobinopathies Drugs Market Analysis , 2018 – 2028
          7.4.1.  Asia Pacific Hemoglobinopathies Drugs Market Size (US$), By Country, 2018 – 2028 
               7.4.1.1. China
               7.4.1.2. Japan
               7.4.1.3. India
               7.4.1.4. Rest of Asia Pacific
          7.4.2. Asia Pacific Hemoglobinopathies Drugs Market Size (US$), By Type, 2018 – 2028
          7.4.3. Asia Pacific Hemoglobinopathies Drugs Market Size (US$), By Application, 2018 – 2028
          7.4.4. Asia Pacific Hemoglobinopathies Drugs Market Size (US$), By End-use, 2018 – 2028
     7.5. Latin America Hemoglobinopathies Drugs Market Analysis, 2018 – 2028 
          7.5.1.  Latin America Hemoglobinopathies Drugs Market Size (US$), By Country, 2018 – 2028 
               7.5.1.1. Brazil
               7.5.1.2. Mexico
               7.5.1.3. Rest of Latin America
          7.5.2. Latin America Hemoglobinopathies Drugs Market Size (US$), By Type, 2018 – 2028
          7.5.3. Latin America Hemoglobinopathies Drugs Market Size (US$), By Application, 2018 – 2028
          7.5.4. Latin America Hemoglobinopathies Drugs Market Size (US$), By End-use, 2018 – 2028
     7.6. Middle East & Africa (MEA) Hemoglobinopathies Drugs Market Analysis, 2018 – 2028 
          7.6.1.  MEA Hemoglobinopathies Drugs Market Size (US$), By Region, 2018 – 2028 
               7.6.1.1. GCC Countries
               7.6.1.2. South Africa
               7.6.1.3. Rest of MEA
          7.6.2. MEA Hemoglobinopathies Drugs Market Size (US$), By Type, 2018 – 2028
          7.6.3. MEA Hemoglobinopathies Drugs Market Size (US$), By Application, 2018 – 2028
          7.6.4. MEA Hemoglobinopathies Drugs Market Size (US$), By End-use, 2018 – 2028

8. Company Profiles
     8.1. Competitive Analysis 
     8.2. Market Positioning of Key Vendors 
     8.3. Key Strategies adopted by the Leading Players
     8.4. Key Hemoglobinopathies Drugs Providers
        8.4.1 Gamida Cell
                8.1.1 Business Description
                8.1.2 Gamida Cell Geographic Operations
                8.1.3 Gamida Cell Financial Information
                8.1.4 Gamida Cell Product Positions/Portfolio
                8.1.5 Gamida Cell Key Developments
        8.4.2 Alnylam Pharmaceuticals
                8.2.1 Business Description
                8.2.2 Alnylam Pharmaceuticals Geographic Operations
                8.2.3 Alnylam Pharmaceuticals Financial Information
                8.2.4 Alnylam Pharmaceuticals Product Positions/Portfolio
                8.2.5 Alnylam Pharmaceuticals Key Developments
        8.4.3 Biogen Idec
                8.3.1 Business Description
                8.3.2 Biogen Idec Geographic Operations
                8.3.3 Biogen Idec Financial Information
                8.3.4 Biogen Idec Product Positions/Portfolio
                8.3.5 Biogen Idec Key Developments
        8.4.4 Sangamo BioSciences Inc.
                8.4.1 Business Description
                8.4.2 Sangamo BioSciences Inc. Geographic Operations
                8.4.3 Sangamo BioSciences Inc. Financial Information
                8.4.4 Sangamo BioSciences Inc. Product Positions/Portfolio
                8.4.5 Sangamo BioSciences Inc. Key Developments
        8.4.5 Genetix Pharmaceuticals/Bluebird Bio
                8.5.1 Business Description
                8.5.2 Genetix Pharmaceuticals/Bluebird Bio Geographic Operations
                8.5.3 Genetix Pharmaceuticals/Bluebird Bio Financial Information
                8.5.4 Genetix Pharmaceuticals/Bluebird Bio Product Positions/Portfolio
                8.5.5 Genetix Pharmaceuticals/Bluebird Bio Key Developments
        8.4.6 Global Blood Therapeutics Inc.
                8.6.1 Business Description
                8.6.2 Global Blood Therapeutics Inc. Geographic Operations
                8.6.3 Global Blood Therapeutics Inc. Financial Information
                8.6.4 Global Blood Therapeutics Inc. Product Positions/Portfolio
                8.6.5 Global Blood Therapeutics Inc. Key Developments
        8.4.7 Pfizer Inc.
                8.7.1 Business Description
                8.7.2 Pfizer Inc. Geographic Operations
                8.7.3 Pfizer Inc. Financial Information
                8.7.4 Pfizer Inc. Product Positions/Portfolio
                8.7.5 Pfizer Inc. Key Developments
        8.4.8 Mast Therapeutics
                8.8.1 Business Description
                8.8.2 Mast Therapeutics Geographic Operations
                8.8.3 Mast Therapeutics Financial Information
                8.8.4 Mast Therapeutics Product Positions/Portfolio
                8.8.5 Mast Therapeutics Key Developments
        8.4.9 Emmaus Life Sciences, Inc.
                8.9.1 Business Description
                8.9.2 Emmaus Life Sciences, Inc. Geographic Operations
                8.9.3 Emmaus Life Sciences, Inc. Financial Information
                8.9.4 Emmaus Life Sciences, Inc. Product Positions/Portfolio
                8.9.5 Emmaus Life Sciences, Inc. Key Developments
        8.4.10 Prolong Pharmaceuticals
                8.10.1 Business Description
                8.10.2 Prolong Pharmaceuticals Geographic Operations
                8.10.3 Prolong Pharmaceuticals Financial Information
                8.10.4 Prolong Pharmaceuticals Product Positions/Portfolio
                8.10.5 Prolong Pharmaceuticals Key Developments
        8.4.11 Celgene Corporation
                8.11.1 Business Description
                8.11.2 Celgene Corporation Geographic Operations
                8.11.3 Celgene Corporation Financial Information
                8.11.4 Celgene Corporation Product Positions/Portfolio
                8.11.5 Celgene Corporation Key Developments
        8.4.12 HemaQuest Pharmaceuticals
                8.12.1 Business Description
                8.12.2 HemaQuest Pharmaceuticals Geographic Operations
                8.12.3 HemaQuest Pharmaceuticals Financial Information
                8.12.4 HemaQuest Pharmaceuticals Product Positions/Portfolio
                8.12.5 HemaQuest Pharmaceuticals Key Developments

LIST OF TABLES

TABLE 1 Market Snapshot: Global Hemoglobinopathies Drugs Market 
TABLE 2 Impact Indicators 
TABLE 3 Impact Analysis of Drivers and Restraints 
TABLE 4 North America Hemoglobinopathies Drugs Market Revenue, By Type, 2018 – 2028 (US$ Mn) 
TABLE 5 North America Hemoglobinopathies Drugs Market Revenue, By Application, 2018 – 2028 (US$ Mn) 
TABLE 6 North America Hemoglobinopathies Drugs Market Revenue, By End-use, 2018 – 2028 (US$ Mn) 
TABLE 7 Europe Hemoglobinopathies Drugs Market Revenue, By Type, 2018 – 2028 (US$ Mn) 
TABLE 8 Europe Hemoglobinopathies Drugs Market Revenue, By Application, 2018 – 2028 (US$ Mn) 
TABLE 9 Europe Hemoglobinopathies Drugs Market Revenue, By End-use, 2018 – 2028 (US$ Mn) 
TABLE 10 Asia Pacific Hemoglobinopathies Drugs Market Revenue, By Type, 2018 – 2028 (US$ Mn) 
TABLE 11 Asia Pacific Hemoglobinopathies Drugs Market Revenue, By Application, 2018 – 2028 (US$ Mn) 
TABLE 12 Asia Pacific Hemoglobinopathies Drugs Market Revenue, By End-use, 2018 – 2028 (US$ Mn) 
TABLE 13 Latin America Hemoglobinopathies Drugs Market Revenue, By Type, 2018 – 2028 (US$ Mn) 
TABLE 14 Latin America Hemoglobinopathies Drugs Market Revenue, By Application, 2018 – 2028 (US$ Mn) 
TABLE 15 Latin America Hemoglobinopathies Drugs Market Revenue, By End-use, 2018 – 2028 (US$ Mn)
TABLE 16 MEA Hemoglobinopathies Drugs Market Revenue, By Type, 2018 – 2028 (US$ Mn) 
TABLE 17 MEA Hemoglobinopathies Drugs Market Revenue, By Application, 2018 – 2028 (US$ Mn) 
TABLE 18 MEA Hemoglobinopathies Drugs Market Revenue, By End-use, 2018 – 2028 (US$ Mn)

LIST OF FIGURES

FIG. 1 Global Hemoglobinopathies Drugs: Market Segmentation 
FIG. 2 Global Hemoglobinopathies Drugs Market: Research Methodology 
FIG. 3 Top-Down and Bottom-up Approach 
FIG. 4 Global Hemoglobinopathies Drugs Market, By Type, 2019 (US$ Mn) 
FIG. 5 Global Hemoglobinopathies Drugs Market, By Application, 2019 (US$ Mn) 
FIG. 6 Global Hemoglobinopathies Drugs Market, By End-use, 2019 (US$ Mn) 
FIG. 7 Global Hemoglobinopathies Drugs Market, By Geography, 2019 (US$ Mn) 
FIG. 8 Global Hemoglobinopathies Drugs Market Revenue and Growth, 2018 – 2028, (US$ Mn) (Y-o-Y %)
FIG. 9 Attractive Investment Proposition 
FIG. 10 Market Positioning of Key Hemoglobinopathies Drugs Providers, 2019
FIG. 11 Global Hemoglobinopathies Drugs Market Revenue Contribution, By Type, 2019 & 2028 (Value %) 
FIG. 12 Global Hemoglobinopathies Drugs Market Revenue Contribution, By Application, 2019 & 2028 (Value %) 
FIG. 13 Global Hemoglobinopathies Drugs Market Revenue Contribution, By End-use, 2019 & 2028 (Value %) 
FIG. 14 North America Hemoglobinopathies Drugs Market Revenue, 2018 – 2028, (US$ Mn) 
FIG. 15 Europe Hemoglobinopathies Drugs Market Revenue, 2018 – 2028, (US$ Mn) 
FIG. 16 Asia Pacific Hemoglobinopathies Drugs Market Revenue, 2018 – 2028, (US$ Mn) 
FIG. 17 Latin America Hemoglobinopathies Drugs Market Revenue, 2018 – 2028, (US$ Mn)
FIG. 18 MEA Hemoglobinopathies Drugs Market Revenue, 2018 – 2028, (US$ Mn)

Key Takeaways:

1. Market value and estimate of the Hemoglobinopathies Drugs market for the period from 2020 to 2028
2. Compounded annual growth rate (CAGR%) for individual segments in various regional markets for a period from 2020 to 2028
3. Value chain analysis
4. Market share study combined with competitive landscape of major players
5. Profiles of major market players covering overall business operations, geographic occurrence, product portfolio, financial status and news coverage 

List of Tables

TABLE  Market Snapshot: Global Hemoglobinopathies Drugs Market
TABLE  Impact Pointers
TABLE  Impact Analysis of Drivers and Restraints
TABLE  North America Hemoglobinopathies Drugs Market Value, By Segment1, 2018 – 2028
TABLE  North America Hemoglobinopathies Drugs Market Value, By Segment2, 2018 – 2028
TABLE  North America Hemoglobinopathies Drugs Market Value, By Country, 2018 – 2028
TABLE  Europe Hemoglobinopathies Drugs Market Value, By Segment1, 2018 – 2028
TABLE  Europe Hemoglobinopathies Drugs Market Value, By Segment2, 2018 – 2028
TABLE  Europe Hemoglobinopathies Drugs Market Value, By Country, 2018 – 2028
TABLE  Asia Pacific Hemoglobinopathies Drugs Market Value, By Segment1, 2018 – 2028
TABLE  Asia Pacific Hemoglobinopathies Drugs Market Value, By Segment2, 2018 – 2028
TABLE  Asia Pacific Hemoglobinopathies Drugs Market Value, By Country, 2018 – 2028
TABLE  Latin America Hemoglobinopathies Drugs Market Value, By Segment1, 2018 – 2028
TABLE  Latin America Hemoglobinopathies Drugs Market Value, By Segment2, 2018 – 2028
TABLE  Latin America Hemoglobinopathies Drugs Market Value, By Country, 2018 – 2028
TABLE  MEA Hemoglobinopathies Drugs Market Value, By Segment1, 2018 – 2028
TABLE  MEA Hemoglobinopathies Drugs Market Value, By Segment2, 2018 – 2028
TABLE  MEA Hemoglobinopathies Drugs Market Value, By Country, 2018 – 2028
TABLE  Gamida Cell: Company Snapshot (Company Details, Geographical Presence, Product Portfolio, Recent News and Announcements)
TABLE  Alnylam Pharmaceuticals: Company Snapshot (Company Details, Geographical Presence, Product Portfolio, Recent News and Announcements)
TABLE  Biogen Idec: Company Snapshot (Company Details, Geographical Presence, Product Portfolio, Recent News and Announcements)
TABLE  Sangamo BioSciences Inc.: Company Snapshot (Company Details, Geographical Presence, Product Portfolio, Recent News and Announcements)
TABLE  Genetix Pharmaceuticals/Bluebird Bio: Company Snapshot (Company Details, Geographical Presence, Product Portfolio, Recent News and Announcements)
TABLE  Global Blood Therapeutics Inc.: Company Snapshot (Company Details, Geographical Presence, Product Portfolio, Recent News and Announcements)
TABLE  Pfizer Inc.: Company Snapshot (Company Details, Geographical Presence, Product Portfolio, Recent News and Announcements)
TABLE  Mast Therapeutics: Company Snapshot (Company Details, Geographical Presence, Product Portfolio, Recent News and Announcements)
TABLE  Emmaus Life Sciences, Inc.: Company Snapshot (Company Details, Geographical Presence, Product Portfolio, Recent News and Announcements)
TABLE  Prolong Pharmaceuticals: Company Snapshot (Company Details, Geographical Presence, Product Portfolio, Recent News and Announcements)
TABLE  Celgene Corporation: Company Snapshot (Company Details, Geographical Presence, Product Portfolio, Recent News and Announcements)
TABLE  HemaQuest Pharmaceuticals: Company Snapshot (Company Details, Geographical Presence, Product Portfolio, Recent News and Announcements)
 

List of Figures

FIG.  Global Hemoglobinopathies Drugs Market: Research Methodology
FIG.  Top-Down and Bottom Up Approach
FIG.  Global Hemoglobinopathies Drugs Market, By Segment1, 2019 (US$ Mn)
FIG.  Global Hemoglobinopathies Drugs Market, By Segment2, 2019 (US$ Mn)
FIG.  Global Hemoglobinopathies Drugs Market, By Geography, 2019 (US$ Mn)
FIG.  Global Hemoglobinopathies Drugs Market Value and Growth, 2018 – 2028, (US$ Mn) (Y-o-Y %)
FIG.  Attractive Investment Proposition
FIG.  Market Positioning of Key Hemoglobinopathies Drugs Providers, 2016
FIG.  Global Hemoglobinopathies Drugs Market Value Share, By Segment1, 2019 & 2028 (% Value)
FIG.  Global Thalassemia Therapy Market Value, 2018 – 2028, (US$ Mn)
FIG.  Global Sickle Cell Disease(SCD) Therapy Market Value, 2018 – 2028, (US$ Mn)
FIG.  Global Other Therapy Market Value, 2018 – 2028, (US$ Mn)
FIG.  Global Hemoglobinopathies Drugs Market Value Share, By Segment2, 2019 & 2028 (% Value)
FIG.  Global Alpha Thalassemia Market Value, 2018 – 2028, (US$ Mn)
FIG.  Global Beta thalassemia Market Value, 2018 – 2028, (US$ Mn)
FIG.  Global Sickle Cell Disease Market Value, 2018 – 2028, (US$ Mn)
FIG.  Global Hb Variants Diseases Market Value, 2018 – 2028, (US$ Mn)
FIG.  U.S. Hemoglobinopathies Drugs Market Value, 2018 – 2028, (US$ Mn)
FIG.  Canada Hemoglobinopathies Drugs Market Value, 2018 – 2028, (US$ Mn)
FIG.  UK Hemoglobinopathies Drugs Market Value, 2018 – 2028, (US$ Mn)
FIG.  Germany Hemoglobinopathies Drugs Market Value, 2018 – 2028, (US$ Mn)
FIG.  France Hemoglobinopathies Drugs Market Value, 2018 – 2028, (US$ Mn)
FIG.  Rest of Europe Hemoglobinopathies Drugs Market Value, 2018 – 2028, (US$ Mn)
FIG.  China Hemoglobinopathies Drugs Market Value, 2018 – 2028, (US$ Mn)
FIG.  Japan Hemoglobinopathies Drugs Market Value, 2018 – 2028, (US$ Mn)
FIG.  India Hemoglobinopathies Drugs Market Value, 2018 – 2028, (US$ Mn)
FIG.  Rest of Asia Pacific Hemoglobinopathies Drugs Market Value, 2018 – 2028, (US$ Mn)
FIG.  Mexico Hemoglobinopathies Drugs Market Value, 2018 – 2028, (US$ Mn)
FIG.  Brazil Hemoglobinopathies Drugs Market Value, 2018 – 2028, (US$ Mn)
FIG.  Rest of Latin America Hemoglobinopathies Drugs Market Value, 2018 – 2028, (US$ Mn)
FIG.  GCC Countries Hemoglobinopathies Drugs Market Value, 2018 – 2028, (US$ Mn)
FIG.  South Africa Hemoglobinopathies Drugs Market Value, 2018 – 2028, (US$ Mn)
FIG.  Rest of MEA Hemoglobinopathies Drugs Market Value, 2018 – 2028, (US$ Mn)